The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later.
In this review, we describe how clinical investigators addressed some of the challenges in prostate cancer chemotherapy trials 20 years ago, and we indicate what has evolved in the field since that time. We consider the impact that prostate-specific antigen measurement had in this setting, evolving clinical paradigms, multidisciplinary programs, and the current armamentarium of cancer treatment, including targeted molecular therapy, for patients with hormone-refractory disease.
Eisenberger
Mario A
MA
The Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA. marioe@jhmi.edu
Sinibaldi
Victoria W
VW
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D024221:Antineoplastic Protocols; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen